Despite being the most frequently altered oncogenic protein in solid tumours, KRAS has
historically been considered 'undruggable'owing to a lack of pharmacologically targetable …

Myeloid cells are pivotal within the immunosuppressive tumour microenvironment. The
accumulation of tumour-modified myeloid cells derived from monocytes or neutrophils …

Importance Although tumor mutation burden (TMB) has been explored as a potential
biomarker of immunotherapy efficacy in solid tumors, there still is a lack of consensus about …

Diagnosis of tumour type allows prognostication and triage for biomarker testing (see the
Supplementary Material Section 3 and Supplementary Figure S1, available at https://doi …

Molecular modifiers of KRASG12C inhibitor (KRASG12Ci) efficacy in advanced KRAS G12C-
mutant NSCLC are poorly defined. In a large unbiased clinicogenomic analysis of 424 …

After decades of efforts, we have recently made progress into targeting KRAS mutations in
several malignancies. Known as the 'holy grail'of targeted cancer therapies, KRAS is the …

Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …

Importance Currently, predictive biomarkers for response to immune checkpoint inhibitor
(ICI) therapy in lung cancer are limited. Identifying such biomarkers would be useful to refine …

Non-small-cell lung cancer (NSCLC) has become a paradigm of precision medicine, with
the discovery of numerous disease subtypes defined by specific oncogenic driver mutations …

Immunotherapy including immune checkpoint inhibitors (ICIs) has become the backbone of
treatment for most lung cancers with advanced or metastatic disease. In addition, they have …